This retrospective analysis aimed to evaluate the correlation between HER-2 data and pCR of HER-2-positive breast cancer patients treated with dual-target neoadjuvant therapy of trastuzumab and pertuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.